The Experts below are selected from a list of 62763 Experts worldwide ranked by ideXlab platform
Arlene O Siefkerradtke - One of the best experts on this subject based on the ideXlab platform.
-
Neoadjuvant Chemotherapy improves survival of patients with upper tract urothelial carcinoma
Cancer, 2014Co-Authors: Sima P Porten, Arlene O Siefkerradtke, Lianchun Xiao, Vitaly Margulis, Ashish M Kamat, Christopher G Wood, E Jonasch, Colin P Dinney, Surena F MatinAbstract:Background High-grade upper tract urothelial carcinoma (UTUC) is frequently upstaged after surgery and is associated with uniformly poor survival. Neoadjuvant Chemotherapy may offer a way to improve clinical outcomes. We compare the survival rates of UTUC patients who received Neoadjuvant Chemotherapy prior to surgery with patients who did not.
-
refining patient selection for Neoadjuvant Chemotherapy before radical cystectomy
The Journal of Urology, 2014Co-Authors: Stephen H Culp, Sima P Porten, Arlene O Siefkerradtke, Rian J Dickstein, Barton H Grossman, Shanna Pretzsch, Siamak Daneshmand, Susan Groshen, Randall E Millikan, Bogdan CzerniakAbstract:Purpose: We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without Neoadjuvant Chemotherapy to confirm the utility of existing clinical tools to identify low risk patients who could be treated with radical cystectomy alone and a high risk group most likely to benefit from Neoadjuvant Chemotherapy.Materials and Methods: We identified patients with muscle invasive bladder cancer who underwent radical cystectomy without Neoadjuvant Chemotherapy at our institution between 2000 and 2010. Patients were considered high risk based on the clinical presence of hydroureteronephrosis, cT3b-T4a disease, and/or histological evidence of lymphovascular invasion, micropapillary or neuroendocrine features on transurethral resection. We evaluated survival (disease specific, progression-free and overall) and rate of pathological up staging. An independent cohort of patients from another institution was used to confirm our findings.Results: We identified 98 high risk and 1...
-
perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after Neoadjuvant Chemotherapy
Urology, 2011Co-Authors: M Z Rajput, Arlene O Siefkerradtke, Ashish M Kamat, Colin P Dinney, J Clavellhernandez, H B Grossman, Surena F MatinAbstract:Objectives To determine the effect of Neoadjuvant Chemotherapy on the surgical outcomes in patients undergoing laparoscopic radical nephroureterectomy (LNUX) for upper urinary tract urothelial carcinoma (UTUC). Methods We performed a retrospective review of all patients with UTUC who had undergone LNUX at our institution from January 2003 to June 2010. We compared the differences in demographic, clinicopathologic, and operative parameters, including the estimated blood loss, duration of surgery, length of postoperative hospitalization, and number of complications, between the patients who had undergone LNUX after Neoadjuvant Chemotherapy and those who had undergone LNUX without Neoadjuvant Chemotherapy. Logistic regression analysis was performed to identify the predictors of complications. Results We identified 82 patients with UTUC who had undergone LNUX. Of these patients, 26 had received Neoadjuvant Chemotherapy. The patients who had undergone LNUX after Neoadjuvant Chemotherapy had a greater body mass index, greater biopsy tumor grade, and longer operative time than those who had undergone LNUX without Neoadjuvant Chemotherapy. The patients who received Neoadjuvant Chemotherapy had undergone regional lymphadenectomy more often, with more lymph nodes and lymphoadipose tissue removed, than those who had not received Neoadjuvant Chemotherapy. Neoadjuvant Chemotherapy resulted in a 15% complete remission rate. No differences in the median estimated blood loss, intraoperative transfusion rate, or length of hospitalization between the 2 groups were found. The perioperative complication rates were similar in both groups. Conclusions We found no differences in the surgical outcomes between those patients who had undergone LNUX after Neoadjuvant Chemotherapy and those who had undergone LNUX without Neoadjuvant Chemotherapy. Our findings support the use of LNUX for selected patients undergoing Neoadjuvant Chemotherapy for UTUC.
Surena F Matin - One of the best experts on this subject based on the ideXlab platform.
-
Neoadjuvant Chemotherapy improves survival of patients with upper tract urothelial carcinoma
Cancer, 2014Co-Authors: Sima P Porten, Arlene O Siefkerradtke, Lianchun Xiao, Vitaly Margulis, Ashish M Kamat, Christopher G Wood, E Jonasch, Colin P Dinney, Surena F MatinAbstract:Background High-grade upper tract urothelial carcinoma (UTUC) is frequently upstaged after surgery and is associated with uniformly poor survival. Neoadjuvant Chemotherapy may offer a way to improve clinical outcomes. We compare the survival rates of UTUC patients who received Neoadjuvant Chemotherapy prior to surgery with patients who did not.
-
perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after Neoadjuvant Chemotherapy
Urology, 2011Co-Authors: M Z Rajput, Arlene O Siefkerradtke, Ashish M Kamat, Colin P Dinney, J Clavellhernandez, H B Grossman, Surena F MatinAbstract:Objectives To determine the effect of Neoadjuvant Chemotherapy on the surgical outcomes in patients undergoing laparoscopic radical nephroureterectomy (LNUX) for upper urinary tract urothelial carcinoma (UTUC). Methods We performed a retrospective review of all patients with UTUC who had undergone LNUX at our institution from January 2003 to June 2010. We compared the differences in demographic, clinicopathologic, and operative parameters, including the estimated blood loss, duration of surgery, length of postoperative hospitalization, and number of complications, between the patients who had undergone LNUX after Neoadjuvant Chemotherapy and those who had undergone LNUX without Neoadjuvant Chemotherapy. Logistic regression analysis was performed to identify the predictors of complications. Results We identified 82 patients with UTUC who had undergone LNUX. Of these patients, 26 had received Neoadjuvant Chemotherapy. The patients who had undergone LNUX after Neoadjuvant Chemotherapy had a greater body mass index, greater biopsy tumor grade, and longer operative time than those who had undergone LNUX without Neoadjuvant Chemotherapy. The patients who received Neoadjuvant Chemotherapy had undergone regional lymphadenectomy more often, with more lymph nodes and lymphoadipose tissue removed, than those who had not received Neoadjuvant Chemotherapy. Neoadjuvant Chemotherapy resulted in a 15% complete remission rate. No differences in the median estimated blood loss, intraoperative transfusion rate, or length of hospitalization between the 2 groups were found. The perioperative complication rates were similar in both groups. Conclusions We found no differences in the surgical outcomes between those patients who had undergone LNUX after Neoadjuvant Chemotherapy and those who had undergone LNUX without Neoadjuvant Chemotherapy. Our findings support the use of LNUX for selected patients undergoing Neoadjuvant Chemotherapy for UTUC.
Bogdan Czerniak - One of the best experts on this subject based on the ideXlab platform.
-
refining patient selection for Neoadjuvant Chemotherapy before radical cystectomy
The Journal of Urology, 2014Co-Authors: Stephen H Culp, Sima P Porten, Arlene O Siefkerradtke, Rian J Dickstein, Barton H Grossman, Shanna Pretzsch, Siamak Daneshmand, Susan Groshen, Randall E Millikan, Bogdan CzerniakAbstract:Purpose: We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without Neoadjuvant Chemotherapy to confirm the utility of existing clinical tools to identify low risk patients who could be treated with radical cystectomy alone and a high risk group most likely to benefit from Neoadjuvant Chemotherapy.Materials and Methods: We identified patients with muscle invasive bladder cancer who underwent radical cystectomy without Neoadjuvant Chemotherapy at our institution between 2000 and 2010. Patients were considered high risk based on the clinical presence of hydroureteronephrosis, cT3b-T4a disease, and/or histological evidence of lymphovascular invasion, micropapillary or neuroendocrine features on transurethral resection. We evaluated survival (disease specific, progression-free and overall) and rate of pathological up staging. An independent cohort of patients from another institution was used to confirm our findings.Results: We identified 98 high risk and 1...
Sima P Porten - One of the best experts on this subject based on the ideXlab platform.
-
Neoadjuvant Chemotherapy improves survival of patients with upper tract urothelial carcinoma
Cancer, 2014Co-Authors: Sima P Porten, Arlene O Siefkerradtke, Lianchun Xiao, Vitaly Margulis, Ashish M Kamat, Christopher G Wood, E Jonasch, Colin P Dinney, Surena F MatinAbstract:Background High-grade upper tract urothelial carcinoma (UTUC) is frequently upstaged after surgery and is associated with uniformly poor survival. Neoadjuvant Chemotherapy may offer a way to improve clinical outcomes. We compare the survival rates of UTUC patients who received Neoadjuvant Chemotherapy prior to surgery with patients who did not.
-
refining patient selection for Neoadjuvant Chemotherapy before radical cystectomy
The Journal of Urology, 2014Co-Authors: Stephen H Culp, Sima P Porten, Arlene O Siefkerradtke, Rian J Dickstein, Barton H Grossman, Shanna Pretzsch, Siamak Daneshmand, Susan Groshen, Randall E Millikan, Bogdan CzerniakAbstract:Purpose: We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without Neoadjuvant Chemotherapy to confirm the utility of existing clinical tools to identify low risk patients who could be treated with radical cystectomy alone and a high risk group most likely to benefit from Neoadjuvant Chemotherapy.Materials and Methods: We identified patients with muscle invasive bladder cancer who underwent radical cystectomy without Neoadjuvant Chemotherapy at our institution between 2000 and 2010. Patients were considered high risk based on the clinical presence of hydroureteronephrosis, cT3b-T4a disease, and/or histological evidence of lymphovascular invasion, micropapillary or neuroendocrine features on transurethral resection. We evaluated survival (disease specific, progression-free and overall) and rate of pathological up staging. An independent cohort of patients from another institution was used to confirm our findings.Results: We identified 98 high risk and 1...
Stephen H Culp - One of the best experts on this subject based on the ideXlab platform.
-
refining patient selection for Neoadjuvant Chemotherapy before radical cystectomy
The Journal of Urology, 2014Co-Authors: Stephen H Culp, Sima P Porten, Arlene O Siefkerradtke, Rian J Dickstein, Barton H Grossman, Shanna Pretzsch, Siamak Daneshmand, Susan Groshen, Randall E Millikan, Bogdan CzerniakAbstract:Purpose: We evaluated the survival of patients with muscle invasive bladder cancer undergoing radical cystectomy without Neoadjuvant Chemotherapy to confirm the utility of existing clinical tools to identify low risk patients who could be treated with radical cystectomy alone and a high risk group most likely to benefit from Neoadjuvant Chemotherapy.Materials and Methods: We identified patients with muscle invasive bladder cancer who underwent radical cystectomy without Neoadjuvant Chemotherapy at our institution between 2000 and 2010. Patients were considered high risk based on the clinical presence of hydroureteronephrosis, cT3b-T4a disease, and/or histological evidence of lymphovascular invasion, micropapillary or neuroendocrine features on transurethral resection. We evaluated survival (disease specific, progression-free and overall) and rate of pathological up staging. An independent cohort of patients from another institution was used to confirm our findings.Results: We identified 98 high risk and 1...
